

Unveiling a Rare Cause of Dysphagia

Ana Rita Graça^a Luís Santos^a Marta Gravito-Soares^{a, b}

Elisa Gravito-Soares^{a, b} João Martins Gama^c Pedro Narra Figueiredo^{a, b}

^aGastroenterology Department, Coimbra Hospital and University Centre, Coimbra, Portugal; ^bFaculty of Medicine, University of Coimbra, Coimbra, Portugal; ^cAnatomic Pathology Department, Coimbra Hospital and University Centre, Coimbra, Portugal

Keywords

Dysphagia · Esophagus · Primary malignant melanoma

Abstract

Introduction: Malignant melanoma of the esophagus is an uncommon cause of dysphagia and accounts for only 0.1–0.2% of esophageal neoplasms. Diagnosis is based on esophagogastroduodenoscopy (EGD) with biopsies and immunohistochemical analysis, the latter being crucial in the amelanocytic variant. Gastrointestinal melanomas are more invasive and comprise poorer prognosis than cutaneous melanomas. **Case Presentation:** The authors present the case of a 70-year-old woman admitted to the emergency department for progressive dysphagia with 2 months of evolution. EGD revealed the presence of an extensive, eccentric lesion, occupying approximately half of the luminal circumference at the level of the distal esophagus with circumferential involvement of the esophagogastric junction and cardia. Thoracoabdominopelvic computed tomography and positron emission tomography showed signs of advanced disease. The initial endoscopic biopsies were inconclusive, and EGD was repeated with multiple biopsies directed at the most infiltrative areas, whose histopathological analysis with immunohistochemistry revealed neoplastic cells with marked nuclear positivity for SOX10 and cytoplasmic positivity for vimentin, Melan-A, and HMB45 with absence of melanin pigment, findings suggestive of esophagocardiac amelanocytic malignant melanoma. In a

multidisciplinary team meeting, the neoplasm was deemed unresectable, and the proposal was for esophageal stent placement and palliative hormone therapy. **Discussion:** Primary amelanocytic malignant melanoma is an exceptionally rare neoplasm and an extremely uncommon cause of dysphagia. In this context, we present a compelling case study that underscores the rarity of this histological type, the importance of directing biopsies to the most suspicious areas of the lesion to increase diagnostic yield, the need for a high clinical suspicion, and the atypical endoscopic presentation associated with the amelanocytic subtype.

© 2025 The Author(s).
Published by S. Karger AG, Basel

Desvendando um caso raro de disfagia

Palavras Chave

Disfagia · Esófago · Melanoma maligno primário

Resumo

Introdução: O melanoma maligno do esófago é uma causa rara de disfagia e corresponde apenas a 0.1–0.2% das neoplasias esofágicas. O diagnóstico baseia-se na

Ana Rita Graça and Luís Santos are joint first authors and contributed equally.

endoscopia digestiva alta (EDA) com biópsias e estudo imunohistoquímico dirigido, sendo esta última crucial na variante amelanocítica. Os melanomas gastrointestinais são mais invasivos e têm um prognóstico mais reservado do que os melanomas cutâneos. **Apresentação do caso:** Os autores apresentam o caso de uma mulher de 70 anos admitida no serviço de urgência por disfagia progressiva com 2 meses de evolução. EDA revelou a presença de uma lesão extensa, excêntrica, ocupando cerca de ½ da circunferência luminal a nível do esôfago distal com envolvimento circunferencial da transição esôfago-gástrica e cárdia. Tomografia Computarizada (TC) toracoabdominopélvica e Tomografia por Emissão de Pósitrons (PET) com sinais de doença avançada. As biópsias endoscópicas iniciais foram inconclusivas, tendo-se repetido EDA com realização de múltiplas biópsias dirigidas às áreas mais infiltrativas, cuja análise histopatológica com estudo imunohistoquímico revelou células neoplásicas com marcada positividade nuclear para SOX10 e citoplasmática para vimentina, MELAN A e HMB45 com ausência de pigmento de melanina, achados sugestivos de melanoma maligno amelanocítico esofagocárdico. Em reunião multidisciplinar, a neoplasia foi considerada irresssecável, tendo sido proposta para colocação de prótese esofágica e quimioterapia com intuito paliativo. **Discussão:** O melanoma maligno amelanocítico primário é uma neoplasia excepcionalmente rara e uma causa extremamente incomum de disfagia. Neste contexto, os autores apresentam um caso clínico que destaca a raridade desse tipo histológico, a importância de direcionar as biópsias para as áreas mais suspeitas da lesão para aumentar o rendimento diagnóstico, a necessidade de um elevado índice de suspeição clínica e a apresentação endoscópica atípica associada ao subtipo amelanocítico.

© 2025 The Author(s).
Published by S. Karger AG, Basel

Introduction

Melanoma is a neoplasm originating from melanocytes, with cutaneous location being the most prevalent [1]. Primary mucosal melanomas arise from melanocytes located in the mucous membranes lining the respiratory, gastrointestinal, and urogenital tracts [2]. Primary gastrointestinal mucosal melanoma can occur anywhere in the gastrointestinal mucosa but is more common in the anorectal region (31.4% in the anal canal and 22.2% in the rectum), followed by the oropharyngeal area (32.8%). The esophagus (5.9%), stomach (2.7%), small intestine (2.3%),

gallbladder (1.4%), and large intestine (0.9%) constitute extremely rare locations for primary melanoma [2].

Malignant melanoma of the esophagus is an uncommon cause of dysphagia and accounts for only 0.1–0.2% of esophageal neoplasms [3]. Most cases are located in the upper and middle thirds, consistent with the distribution of melanocytes in the esophageal mucosa [2]. It is more common in men (2:1), with an average age at diagnosis of 60 years [4]. The most frequent symptom is dysphagia, though weight loss and retrosternal pain are often associated [2, 4]. Diagnosis is based on esophagogastroduodenoscopy (EGD) with biopsies and immunohistochemical analysis, the latter being crucial in the amelanocytic variant [4]. Gastrointestinal melanomas are more invasive and comprise poorer prognosis than cutaneous melanomas, with overall survival of less than 5% at 5 years [2, 4, 5]. We report the case of a 70-year-old woman who experienced dysphagia, retrosternal pain, and weight loss, ultimately diagnosed with primary amelanotic malignant melanoma of the esophagus.

Case Report

A 70-year-old woman with a medical history of epilepsy, arterial hypertension, and depressive disorder was admitted to the emergency department due to a clinical condition that had been evolving for 2 months. Initially, she experienced dysphagia with solids (dysphagia score 2) [6], which progressed to dysphagia with solids and liquids (dysphagia score 4) [6] in the previous 2 days. This was accompanied by retrosternal pain, a 50% loss of body weight, and painful cervical adenopathies. She also had a slight anterior cervical swelling, related to a previous diagnosis of non-toxic multinodular goiter. There was no history of alcohol abuse or smoking. Empirical antibiotic therapy was prescribed by a primary care physician, but there was no clinical improvement. Blood tests showed a normocytic normochromic anemia with hemoglobin of 10.6 g/dL (normal range 11.8–15.8 g/dL), mean corpuscular volume of 91.6 fL (normal range 80–101 fL), and mean corpuscular hemoglobin of 31.9 pg (normal range 27–34 pg), along with a C-reactive protein level of 5.4 mg/dL (normal range <0.50 mg/dL). The EGD revealed an esophageal lesion with luminal protrusion, occupying about half of the luminal circumference, extending from 30 cm from the dental arch to the esophagogastric junction and cardia. There were extensive ulceration and friability of the mucosa at the cardia level, and multiple biopsies were performed (shown in Fig. 1). The cervical-thoracic-abdominopelvic computed tomography scan




Fig. 1. EGD reveals the presence of an extensive and eccentric lesion starting at 30 cm from the dental arch, occupying approximately half of the luminal circumference at the level of the distal esophagus. There is circumferential involvement of the esophagogastric junction and the cardia, with infiltration of the mucosa and extensive ulceration and friability.



Fig. 2. Cervical-thoracic-abdominopelvic computed tomography scan showing a solid and heterogeneous expansive lesion, starting at the level of D8-D9 and extending caudally for approximately 14 cm, reaching the cranial portion of the gastric fundus with contact with the thoracic aorta and posterior cardiac chambers. Additionally, a voluminous adenopathy is observed in the region of the celiac trunk.




Fig. 3. 18-Fluorodeoxyglucose positron emission tomography revealing an esophagogastric lesion with high metabolic activity, as well as adenopathies along the lesser curvature of the stomach, forming a conglomerate of 40 × 30 mm.

showed a solid and heterogeneous expansive lesion in the distal third of the esophagus, starting at the level of D8-D9 and extending caudally for approximately 14 cm, reaching the cranial portion of the gastric fundus that contact with the thoracic aorta and posterior cardiac chambers, and a voluminous adenopathy in the region of the celiac trunk (shown in Fig. 2). The positron emission

tomography scan with 18-fluorodeoxyglucose showed the previously described lesion with a high metabolic activity, as well as adenopathies along the lesser curvature of the stomach, forming a conglomerate of 40 × 30 mm (shown in Fig. 3). Initial endoscopic biopsies were inconclusive, leading to repeated EGD with multiple biopsies directed at the most suspicious areas. The histopathological




Fig. 4. Anatomopathological evaluation. **a** H&E 200 $\times$, a neoplasm composed of epithelioid cells with scattered apoptotic bodies, is seen. **b** No immunostaining for AE1/AE3 was seen. **c** CD20 was negative. **d** CD3 was also negative. **e** Diffuse nuclear positivity for SOX10 is seen. **f** Diffuse cytoplasmic positivity for Melan-A.

analysis with immunohistochemical staining revealed neoplastic cells with marked nuclear positivity for SOX10 and cytoplasmic positivity for vimentin, Melan-A, and HMB45, with the absence of melanin pigment (shown in Fig. 4). Dermatology evaluation was requested to exclude cutaneous, ocular, vaginal, or anal melanomas. The final diagnosis was determined to be a primary esophagocardiac malignant melanoma, amelanotic variant, grade 2, stage IV, according to the TNM classification [7]. In a multidisciplinary team meeting, the neoplasm was deemed unresectable, and the proposal was for esophageal stent placement and palliative hormone therapy. Unfortunately, the patient died 20 days after the diagnosis, before initiating chemotherapy.

Discussion

Primary malignant melanoma of the esophagus is infrequent, with only 300 cases described in the literature, and a slightly higher incidence in males [4]. It represents

0.1–0.2% of esophageal neoplasms, of which 10–25% are amelanocytic, comprising less than 0.05% of all melanoma subtypes [3, 5]. The pathogenesis for developing a primary esophageal melanoma remains poorly understood and there are no significant risk factors for this malignant condition. Table 1 describes the published cases regarding esophageal amelanocytic melanoma. The presentation is similar to other histological types of esophageal neoplasms, manifesting as dysphagia. Diagnosis requires a high degree of suspicion, based on endoscopic findings and directed histological and immunohistochemical analysis [8].

EGD can be highly suspicious in the melanocytic subtype, presenting as a dark, purple, or reddish luminal esophageal bulge, depending on the amount of melanin. However, in the amelanocytic subtype, the mucosa may appear normal in color, as in the presented case, making it challenging to differentially diagnose from other primary esophageal lesions such as squamous cell carcinoma or adenocarcinoma, as well as extrinsic lesions with esophagogastric compression and/or infiltration [5].

Table 1. Description of published cases of primary amelanotic malignant melanoma

Reference	Gender/ age	Symptoms	Location/ endoscopic findings	Histology/ IHQ	TNM classification/ stage	Treatment	Prognosis
Koga et al. [9], 2019	Female/ 86	Dysphagia	Inferior esophagus/ polypoid	Squamous cell carcinoma/S- 100, HMB45, Melan-A	T2N0M0/II	Surgery	No recurrence after 1 month of surgery
Zhang et al. [10], 2019	Female/ 49	Dysphagia + retrosteral pain	NE/polypoid	S-100, HMB45, Melan-A	NE	Hormone therapy	Survival of at least 24 months
Kobayashi et al. [11], 2018	Male/69	NE	Distal esophagus/ sessile	S-100, SOX10, KBA.62, tyrosinase	NE	Surgery	No recurrence after 1.5 years
Bisceglia et al. [12], 2011	Male/69	Abdominal pain + melena	Distal esophagus and cardia/ polypoid	S-100, HMB45, Melan-A, vimentin	T1N0Mx	Surgery	Died 14 months after surgery
Stringa et al. [13], 2006	Male/59	Dysphagia + weight loss	Distal esophagus/ polypoid	S-100, HMB45, Melan-A, vimentin	NE	Surgery	Abdominal metastases 13 months after surgery
Taniyama et al. [14], 1990	Female/ 76	Dysphagia	Middle esophagus/ polypoid	NSE, S-100	T3NxM1	Surgery	Died 6 months after surgery
Tsukamoto et al. [15], 2021	Male/76	Screening after <i>Helicobacter pylori</i> eradication	Cardia	S-100, HMB45	T2N0M0	Surgery immunotherapy	Liver metastases 4 months after surgery
Susuki et al. [16], 2005	Male/58	Assymptomatic	Middle esophagus/ sessile and ulcerated	HMB45	T3N1M0	Surgery Adjuvant chemotherapy	Survival of at least 6 years
De Simone et al. [17], 2006	Female/ 58	Dysphagia + retrosteral pain + weight loss	Middle esophagus/ polypoid	S-100, HMB45	T1N0M0	Surgery	Died 16 months after surgery
Heidemann et al. [18], 2005	Male/75	Dysphagia + retrosteral pain + weight loss	Distal esophagus/ polypoid and ulcerated	HMB45, vimentin	T1 N1 M0	Surgery	Recurrence at the anastomosis 7 months after surgery
Kransfelder et al. [19], 2008	Male/57	Dysphagia + odynophagia + weight loss	Distal esophagus and cardia/ polypoid and ulcerated	S-100, HMB45	T3N0M0	Surgery	Died 4 months after diagnosis
Loftus et al. [20], 1994	Female/ 80	Dysphagia + odynophagia + weight loss	Distal esophagus/ polypoid	S-100, HMB45, vimentin	T1/2N0M0	Surgery	Died after surgery due to aspiration pneumonia

Additionally, secondary involvement of the lower esophageal sphincter should be part of the differential diagnosis, more commonly due to direct invasion, as in the case of primary neoplasms of the distal esophagus and proximal stomach, or metastasis, such as lung neoplasia, malignant mesothelioma, breast neoplasia, among others. Other benign conditions, such as post-surgery complications, leiomyoma, amyloidosis, neurofibromatosis, systemic sclerosis, and Chagas disease, should also be considered [21].

The histological examination with immunohistochemical staining of the amelanocytic subtype of melanoma reveals epithelioid neoplastic cells with indistinct borders, with moderate pleomorphism, central nucleoli, and eosinophilic cytoplasm, lacking melanin pigment but showing immunohistochemical positivity for specific melanoma markers such as S-100 (the most sensitive marker, sensitivity of 97–100%, specificity of 75–87%), HMB45 (sensitivity of 69–93%), and Melan-A (sensitivity of 97–100%, specificity of 95–100%, the most specific marker) [9, 11].

The primary malignant melanoma of the esophagus usually presents in advanced stages, with lymph node invasion detected at the time of diagnosis in 40–80% of cases. The prognosis is generally poor compared to cutaneous melanoma, with overall survival rates of less than 5% at 5 years [5, 22].

The treatment depends on the staging and functional status of the patient at the time of diagnosis. Whenever possible, definitive treatment is surgical; however, the best therapeutic strategy is still to be established given the rarity of this clinical condition [23]. In this case, the patient did not have an indication for surgical treatment and was, therefore, proposed for palliative care.

In conclusion, we report a rare case of dysphagia related to primary amelanocytic malignant melanoma of the distal esophagus and cardia, stage IV. This case emphasizes the rarity of this histological type, the im-

portance of directing biopsies to the most suspicious areas of the lesion to increase diagnostic yield, the need for a high clinical suspicion due to its rare etiology, and the atypical endoscopic presentation caused by the amelanocytic subtype. A multidisciplinary approach is essential to determine the best therapeutic strategy.

Statement of Ethics

This type of manuscript (case report) does not require ethical approval due to local laws. Written informed consent was obtained from the patient for publication of this case report and any accompanying iconography.

Conflict of Interest Statement

E.G.-S. and P.N.F. were member of the journal's Editorial Board at the time of submission. The authors have no other conflicts of interest to declare.

Funding Sources

This study was not supported by any sponsor or funder.

Author Contributions

A.R.G. and L.S. contributed equally and were responsible for the drafting of the manuscript. M.G.-S., E.G.-S., J.M.G., and P.N.F. reviewed and edited the manuscript. The manuscript has been read and approved for submission by all named authors.

Data Availability Statement

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

References

- 1 Wang S, Sun S, Liu X, Ge N, Wang G, Guo J, et al. Endoscopic diagnosis of gastrointestinal melanoma. *Scand J Gastroenterol*. 2020;55(3):330–7. <https://doi.org/10.1080/00365521.2020.1734074>
- 2 Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V. Primary mucosal melanomas: a comprehensive review. *Int J Clin Exp Pathol*. 2012;5(8):739–53.
- 3 Li YH, Li X, Zou XP. Primary malignant melanoma of the esophagus: a case report. *World J Gastroenterol*. 2014;20(10):2731–4. <https://doi.org/10.3748/wjg.v20.i10.2731>
- 4 Feldman M, Friedman L, Brandt L, Chung R, Rubin D, Wilcox C. Esophageal tumors. In: Feldman M, Friedman L, Brandt L, editors. *Gastrointestinal and liver disease*. 11th ed. Philadelphia: Elsevier; 2020. p. 717–.
- 5 Cazzato G, Cascardi E, Colagrande A, Lettini T, Resta L, Bizzoca C, et al. The thousand faces of malignant melanoma: a systematic review of the primary malignant melanoma of the esophagus. *Cancers*. 2022; 14(15):3725. <https://doi.org/10.3390/cancers14153725>
- 6 Mellow MH, Pinkas H. Endoscopic laser therapy for malignancies affecting the esophagus and gastroesophageal junction: analysis of technical and functional efficacy. *Arch Intern Med*. 1985;145(8):1443–6. <https://doi.org/10.1001/archinte.145.8.1443>
- 7 Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin*. 2017;67(6):472–92. <https://doi.org/10.3322/caac.21409>

- 8 Chu YM, Hung CS, Huang CS. Primary malignant melanoma of the esophagogastric junction: a case report. *Medicine*. 2021; 100(25):e26467. <https://doi.org/10.1097/MD.00000000000026467>
- 9 Koga N, Kubo N, Saeki H, Sasaki S, Jogo T, Hirose K, et al. Primary amelanotic malignant melanoma of the esophagus: a case report. *Surg Case Rep*. 2019;5(1):4. <https://doi.org/10.1186/s40792-019-0564-2>
- 10 Zhang RX, Li YY, Liu CJ, Wang WN, Cao Y, Bai YH, et al. Advanced primary amelanotic malignant melanoma of the esophagus: A case report. *World J Clin Cases*. 2019;7(19):3160–7. <https://doi.org/10.12998/wjcc.v7.i19.3160>
- 11 Kobayashi J, Fujimoto D, Murakami M, Hirono Y, Goi T. A report of amelanotic malignant melanoma of the esophagus diagnosed appropriately with novel markers: a case report. *Oncol Lett*. 2018;15(6):9087–92. <https://doi.org/10.3892/ol.2018.8479>
- 12 Bisceglia M, Perri F, Tucci A, Tardio M, Panniello G, Vita G, et al. Primary malignant melanoma of the esophagus: a clinicopathologic study of a case with comprehensive literature review. *Adv Anat Pathol*. 2011;18(3):235–52. <https://doi.org/10.1097/PAP.0b013e318216b99b>
- 13 Stringa O, Valdez R, Beguerie JR, Abbruzzese M, Lioni M, Nadales A, et al. Primary amelanotic melanoma of the esophagus. *Int J Dermatol*. 2006;45(10):1207–10. <https://doi.org/10.1111/j.1365-4632.2006.02717.x>
- 14 Taniyama K, Suzuki H, Sakuramachi S, Toyoda T, Matsuda M, Tahara E. Amelanotic malignant melanoma of the esophagus: case report and review of the literature. *Jpn J Clin Oncol*. 1990;20(3):286–95.
- 15 Tsukamoto R, Ihara H, Takase M, Shimazu A, Takei M, Miura H, et al. Immunotherapy against esophageal primary amelanotic malignant melanoma relapse. *J Surg Case Rep*. 2021;2021(10):rjab393. <https://doi.org/10.1093/jscr/rjab393>
- 16 Suzuki Y, Aoyama N, Minamide J, Takata K, Ogata T. Amelanotic malignant melanoma of the esophagus: report of a patient with recurrence successfully treated with chemohormonal therapy. *Int J Clin Oncol*. 2005; 10(3):204–7. <https://doi.org/10.1007/s10147-004-0473-6>
- 17 De Simone P, Gelin M, El Nakadi I. Amelanotic malignant melanoma of the esophagus. Report of a case. *Minerva Chir*. 2006; 61(1):45–9.
- 18 Heidemann J, Lebedz P, Herbst H, Spahn TW, Domagk D, Domschke W, et al. Amelanotic malignant melanoma of the esophagus: case report. *Z Gastroenterol*. 2005;43(6): 597–600. <https://doi.org/10.1055/s-2005-858102>
- 19 Kranzfelder M, Seidl S, Dobritz M, Brucher BL. Amelanotic esophageal malignant melanoma: case report and short review of the literature. *Case Rep Gastroenterol*. 2008;2(2): 224–31. <https://doi.org/10.1159/000137376>
- 20 Loftus BM, Broe P, Johnston O, Leader M. Primary amelanotic malignant melanoma of the oesophagus—a case report. *Ir J Med Sci*. 1994;163(3):128–31. <https://doi.org/10.1007/BF02965971>
- 21 Barnett DR, Balalis GL, Myers JC, Devitt PG. Diagnosis and treatment of pseudoachalasia: how to catch the mimic. *Ann Esophagus*. 2020;3:16. <https://doi.org/10.21037/aoe.2020.03.03>
- 22 Navarro-Ballester A, De Lazaro-De Molina S, Gaona-Morales J. Primary malignant melanoma of the esophagus: a case report and review of the literature. *Am J Case Rep*. 2015; 16:491–5. <https://doi.org/10.12659/AJCR.894041>
- 23 Kuwabara S, Ebihara Y, Nakanishi Y, Asano T, Noji T, Kurashima Y, et al. Primary malignant melanoma of the esophagus treated with subtotal esophagectomy: a case report. *BMC Surg*. 2017;17(1):122. <https://doi.org/10.1186/s12893-017-0326-7>